Crestline Management, L.P.
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Crestline Management, L.P. reported 3 stock positions worth $53.5 million. Its top holding was Denali Therapeutics (DNLI) at 91.9% of the portfolio, followed by Sana Biotechnology (SANA, 4.9%) and 8X8 (EGHT, 3.2%). Compared with Q1 2026, it reduced 1. The biggest sale was Denali Therapeutics (DNLI, shares −14%).
- Most Recent 13F
- Q2 2026
- Location
- FORT WORTH, TX
- CIK
- 0001536054
- Portfolio Value
- $53.5M (Q2 2026)
- SEC Filing
- 0001315863-26-000592 ↗ filed Aug 14, 2026
Holdings Value
Holdings 3 stocks · $53.5M
Portfolio Sells Q1 2026 → Q2 2026
| DNLI Denali Therapeutics Inc. | Reduce -13.6% | 91.90% | +0.16 |
Portfolio Buys Q1 2026 → Q2 2026
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 3 | $53.5M | DNLI, SANA, EGHT |
| Q1 2026Amended | 3 | $46.3M | DNLI, SANA, EGHT |
| Q4 2025 | 3 | $53.3M | DNLI, SANA, EGHT |
| Q3 2025 | 3 | $58.1M | DNLI, SANA, EGHT |
| Q2 2025 | 3 | $62.6M | DNLI, SANA, EGHT |
| Q1 2025 | 3 | $63.2M | DNLI, SANA, EGHT |
| Q4 2024 | 703 | $2.9B | IVV, NVDA, DNLI, QQQ, AMZN |
| Q3 2024 | 508 | $1.8B | SPY, DNLI, NVDA, CRM, AA |
| Q2 2024 | 158 | $1.3B | IVV, DNLI, NVDA, IWM, AAPL |
| Q1 2024 | 155 | $1.1B | DNLI, SANA, SPY, ASML, NI |